136 related articles for article (PubMed ID: 35351838)
1. Analysis of correlation factors influencing the outcome of initial 131I remnant ablative therapy in intermediate- to high-risk patients with papillary thyroid microcarcinoma.
Wu R; Liu W; Li N; Wang X; Sun D; Ji Y; Jia Q; Tan J; Zheng W
Nucl Med Commun; 2022 Jun; 43(6):669-674. PubMed ID: 35351838
[TBL] [Abstract][Full Text] [Related]
2. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract][Full Text] [Related]
3. Impact factors for the outcome of the first
Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
[TBL] [Abstract][Full Text] [Related]
4. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
Pan M; Li Z; Jia M; Lu X
Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of the factors affecting the efficacy of (131)I remnant ablation in patients after thyroidectomy for papillary thyroid microcarcinoma].
Du F; Hu S; Wu C; Cheng Y; Wu LX; Liu JZ; Wu ZF; Li SJ
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):610-613. PubMed ID: 30139032
[No Abstract] [Full Text] [Related]
6. In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.
Zhao T; Liang J; Guo Z; Li T; Lin Y
Clin Nucl Med; 2016 Jun; 41(6):454-8. PubMed ID: 26914559
[TBL] [Abstract][Full Text] [Related]
7. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic
Trevizam PG; Tagliarini JV; Castilho EC; de Alencar Marques M; Kiy Y; Mazeto GMFS
Endocr Res; 2017 Feb; 42(1):42-48. PubMed ID: 27144920
[TBL] [Abstract][Full Text] [Related]
8. Preablative Stimulated Thyroglobulin Levels Can Predict Malignant Potential and Therapeutic Responsiveness of Subcentimeter-Sized, 18F-fluorodeoxyglucose-Avid Cervical Lymph Nodes in Patients With Papillary Thyroid Cancer.
Kwon SY; Kim J; Jung SH; Chong A; Song HC; Bom HS; Min JJ
Clin Nucl Med; 2016 Jan; 41(1):e32-8. PubMed ID: 26164179
[TBL] [Abstract][Full Text] [Related]
9. Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma.
Lang BH; Wong KP; Wan KY; Lo CY
Ann Surg Oncol; 2012 Jan; 19(1):60-7. PubMed ID: 21681379
[TBL] [Abstract][Full Text] [Related]
10. Negative remnant
Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
[TBL] [Abstract][Full Text] [Related]
12. The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of
Zheng W; Rui Z; Wang X; Li N; Tan J; Liu W
Front Endocrinol (Lausanne); 2021; 12():601960. PubMed ID: 34177793
[TBL] [Abstract][Full Text] [Related]
13. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
Torlontano M; Crocetti U; Augello G; D'Aloiso L; Bonfitto N; Varraso A; Dicembrino F; Modoni S; Frusciante V; Di Giorgio A; Bruno R; Filetti S; Trischitta V
J Clin Endocrinol Metab; 2006 Jan; 91(1):60-3. PubMed ID: 16219716
[TBL] [Abstract][Full Text] [Related]
15. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
[TBL] [Abstract][Full Text] [Related]
16. Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center.
Kanokwongnuwat W; Larbcharoensub N; Sriphrapradang C; Suppasilp C; Thamnirat K; Sakulpisuti C; Kositwattanarerk A; Utamakul C; Sritara C; Chamroonrat W
Endocrine; 2022 Jun; 77(1):134-142. PubMed ID: 35476179
[TBL] [Abstract][Full Text] [Related]
17. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy.
de Klerk JM; de Keizer B; Zelissen PM; Lips CM; Koppeschaar HP
Nucl Med Commun; 2000 Jun; 21(6):529-32. PubMed ID: 10894561
[TBL] [Abstract][Full Text] [Related]
18. TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer.
Ju N; Hou L; Song H; Qiu Z; Wang Y; Sun Z; Luo Q; Shen C
Eur Thyroid J; 2023 Aug; 12(4):. PubMed ID: 37022724
[TBL] [Abstract][Full Text] [Related]
19. Random Forest for Predicting Treatment Response to Radioiodine and Thyrotropin Suppression Therapy in Patients With Differentiated Thyroid Cancer But Without Structural Disease.
Sa R; Yang T; Zhang Z; Guan F
Oncologist; 2024 Jan; 29(1):e68-e80. PubMed ID: 37669005
[TBL] [Abstract][Full Text] [Related]
20. A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio to predict the therapeutic response of intermediate‑ and high‑risk differentiated thyroid cancer patients: a bi-center retrospective study.
Wen R; Zhao M; Chen C; Yang Y; Zhang B
Endocrine; 2023 Dec; ():. PubMed ID: 38085420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
